文献速递造血干细胞移植与细胞治疗

合并唑类抗真菌药对移植物抗宿主病患者芦可替尼治疗的影响:REACH2与REACH3的事后分析

Impact of concomitant azoles on ruxolitinib treatment in patients with GVHD: post hoc analyses of REACH2 and REACH3.
PubMed 文献 · Blood Adv · 2025-01-01

该事后分析基于REACH2和REACH3两项3期试验,评估合并唑类抗真菌药对芦可替尼治疗类固醇难治性急性GVHD和类固醇难治性/依赖性慢性GVHD疗效与安全性的影响。结果显示,无论是否合并唑类,芦可替尼较最佳可用治疗均提供更高缓解率,唑类未增加血细胞减少,也未影响芦可替尼中位剂量,但合并唑类者更常需调整剂量。

要点

  • REACH2中合并唑类者第28天总缓解率芦可替尼67.5% vs 最佳可用治疗44.3%(P = .0003)。
  • REACH3中合并唑类者第24周总缓解率芦可替尼46.6% vs 最佳可用治疗29.4%(P = .006)。
  • 合并唑类未增加血细胞减少率,也未影响芦可替尼中位剂量,但更常需调整剂量。

核心结论

  • 总体而言,合并唑类治疗一般耐受良好,在适当优化芦可替尼剂量的情况下未影响治疗结局。
  • 与REACH2/REACH3主要结果一致,无论是否合并唑类,芦可替尼在类固醇难治性急性GVHD和类固醇难治性/依赖性慢性GVHD患者中均较最佳可用治疗提供更大临床获益。

研究设计与样本

  • REACH2和REACH3两项3期试验的事后分析。
  • REACH2纳入类固醇难治性急性GVHD患者,REACH3纳入类固醇难治性/依赖性慢性GVHD患者。
  • REACH2注册号NCT02913261,REACH3注册号NCT03112603。

主要发现

  • REACH2中,合并唑类者第28天总缓解率芦可替尼组67.5% vs 最佳可用治疗组44.3%(P = .0003);未合并唑类者分别为45.9% vs 28.6%。
  • REACH3中,合并唑类者第24周总缓解率芦可替尼组46.6% vs 最佳可用治疗组29.4%(P = .006);未合并唑类者分别为57.1% vs 19.4%(P < .0001)。
  • REACH2中至第28天芦可替尼中位剂量:合并唑类20.0 mg/d(范围9.0-21.0)vs 未合并唑类20.0 mg/d(范围8.4-20.0)。
  • REACH3中至第24周芦可替尼中位剂量:合并唑类19.4 mg/d(范围4.8-20.5)vs 未合并唑类19.9 mg/d(范围5.5-20.0)。
  • 合并唑类未增加REACH2/REACH3中接受芦可替尼治疗患者的血细胞减少率。

临床怎么用

  • 作者指出,合并唑类治疗一般耐受良好,在适当优化芦可替尼剂量的情况下未影响治疗结局。
  • 作者强调,在接受合并唑类的患者中优化芦可替尼剂量十分重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Azole antifungal agents, commonly used for preventing invasive fungal infections in graft-versus-host disease (GVHD), are known to affect ruxolitinib metabolism. Post hoc analyses of the REACH2/REACH3 phase 3 trials examined the impact of these clinically relevant drug interactions on ruxolitinib treatment outcomes in patients with steroid-refractory acute GVHD (aGVHD; REACH2) and steroid-refractory/steroid-dependent chronic GVHD (cGVHD; REACH3). In REACH2, overall response rate (ORR) at day 28 was significantly higher with ruxolitinib vs best available therapy (BAT; 67.5% vs 44.3%; P = .0003) among patients who received concomitant azoles; among those who did not, day 28 ORR was 45.9% vs 28.6%, respectively. In REACH3, ORR at week 24 was significantly higher with ruxolitinib vs BAT in patients who did (46.6% vs 29.4%; P = .006) or did not receive (57.1% vs 19.4%; P < .0001) concomitant azoles. Concomitant azoles neither increased the rate of cytopenias in patients treated with ruxolitinib in REACH2/REACH3, nor affected the median dose of ruxolitinib up to day 28 in REACH2 (azoles/no azoles, 20.0 mg/d [range, 9.0-21.0]/20.0 mg/d [range, 8.4-20.0]) or week 24 in REACH3 (azoles/no azoles, 19.4 mg/d [range, 4.8-20.5]/19.9 mg/d [range, 5.5-20.0]). Patients receiving concomitant azoles were more likely to have ruxolitinib dose modifications in REACH2/REACH3, highlighting the importance of dose optimization in these patients. Overall, concomitant azole treatment was generally well tolerated and did not affect treatment outcomes with appropriate ruxolitinib dose optimization. Consistent with primary REACH2/REACH3 results, ruxolitinib provided greater clinical benefit than BAT in patients with steroid-refractory aGVHD and steroid-refractory/steroid-dependent cGVHD, irrespective of concomitant azole treatment. These trials were registered at www.ClinicalTrials.gov as #NCT02913261 (REACH2) and #NCT03112603 (REACH3).

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Mahmoudjafari Z, Kintsch E, Xue Z, et al. Impact of concomitant azoles on ruxolitinib treatment in patients with GVHD: post hoc analyses of REACH2 and REACH3. Blood Adv. 2025. PMID: 40472328. doi:10.1182/bloodadvances.2025016212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。